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Abstract 12 
The immunomodulatory activity of arabinoxylans (AXs) extracts from cereal 13 
sources have been reported to impart health benefits in terms of immune 14 
enhancement. In this study, further to  the various enzymatic extraction 15 
conditions on extraction yield and structural modification of AXs from the wheat 16 
flour,  nitric oxide (NO) secretion and inducible nitric oxide synthase (iNOS) 17 
expression induced by enzyme extracted AXs and water extracted AXs in a human 18 
monocyte cell cultures U937 were compared. The results of in vitro testing indicate 19 
that AXs treatments not only enhanced NO production, but also iNOS levels in 20 
U937 cells (P < 0.05) compared to untreated cells. The increase in NO secretion 21 
seems correspondingly related to iNOS concentration in cultured cells. Moreover, 22 
 2 
the enzyme-treated AXs with a much higher proportion of low Mw AXs (1-10KDa) 23 
and high A/X ratio (0.83) induced significantly higher (P < 0.05) iNOS expression 24 
(132.2 ± 11.9 μg/ml) than water-extracted AXs treatment (104.3 ± 4.6μg/ml). In 25 
conclusion, an enzymatic method has been developed to efficiently extract AXs 26 
with low Mw and high A/X and with a high yield (81.25%) of the molecular 27 
structures which had a critical influence on the regulation of iNOS expression and 28 
NO production in a cultured human monocytic cell line. 29 
Keywords: Arabinoxylans; wheat flour; Molecular structures; Immunomodulatory 30 
activity; Nitric oxide; Inducible nitric oxide synthase.. 31 
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1. Introduction 33 
Arabinoxylans (AXs) are an important group of hemicelluloses found in the outer-34 
layer and endosperm cell walls of cereals (Izydorczyk & Biliaderis, 1995; Saeed et 35 
al.,2011; Vries et al., 1999). Generally AXs are composed of a backbone of β-1, 4 linked 36 
D-xylopyranosyl residues with L-arabinofuranose subunits. As a dietary fibre, AXs 37 
have been shown to stimulate immune activities in a number of in vitro, in vivo and 38 
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clinical trials (Ghoneum and Matsuura 2004; Zhou et al., 2010; Li, et al., 2015) and 39 
may reduce the risk of infection or cancer (Zhang et al., 2015). It has been proposed 40 
that dietary fibres including AXs, exert their immunomodulation benefits possibly 41 
through two mechanisms: (i) interaction with colonic epithelial cells and innate immune 42 
cells (such as macrophages) which can mediate cytokine production leading to an 43 
improved immune response, (ii) take up by microfold cells, macrophages and dendritic 44 
cells from the intestines and transport to lymph nodes, thus distributingAXs around the 45 
body (Mendis et al., 2016; Samuelsen et al., 2011). Several studies have suggested that 46 
AXs may be considered a potential bioactive food supplement with immunity 47 
improvement properties (Ghoneum and Matsuura 2004; Zhou et al., 2010;  Li et al., 48 
2015). However, the role of AXs in certain specific immune responses such as the 49 
expression of nitric oxide synthases in NO secretion path way still need further 50 
investigation.      51 
Nitric oxide (NO) is a versatile signalling molecule of the immune system 52 
produced by various immunological cells,dendritic cell, NK cell, mast cells and 53 
phagocytic cells. (Bogdan 2000; Forstermann and Sessa 2012). From previous studies, 54 
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the immune functions of NO have been found to involve antimicrobial and anti-tumour 55 
activities in vitro and in vivo (Bogdan 2000; Lechner et al. 2005; Nathan 1992; Pervin 56 
et al. 2001). Inducible NO synthases (iNOS) are critical in generating NO from L-57 
arginine. iNOS can be expressed in immune cells following stimulation by microbial 58 
polysaccharides such as lipopolysaccharides (LPS) and immune cytokines (Bogdan, 59 
2000). Interestingly, recent studies have shown that AXs enhance NO secretion in 60 
murine and human macrophage cell lines (Ghoneum and Matsuura 2004; Li et al., 2015) 61 
and also demonstrated that the molecular structure such as molecular weight (Mw) and 62 
substitution degree (A/X) of cereal AXs may affect their immunomodulatory activities 63 
(Li et al., 2015; Zhang et al., 2016). However, it remains unclear if AXs with different 64 
structures have any function to induce the iNOS expression in NO pathways. 65 
Therefore, the objectives of the current study included to develop an effective and 66 
efficient extraction and modification processes capable of producing high yields of 67 
structurally modified AXs from wheat flour. The sugar compositions and Mw of the 68 
extracted and modified AXs were determined using high performance liquid 69 
chromatography (HPLC). Subsequently, the relationship between molecular structures 70 
 5 
and NO production and iNOS expression in cultured human macrophages were 71 
investigated.  72 
2. Materials and Methods 73 
2.1 Materials 74 
The sample of dried pentosan fraction (moisture content 5.9%) was kindly 75 
provided by Henan Lianhua Monosodium Glutamate Group Co., Ltd (Xiangchen, 76 
Henan, China). Pentopan Mono BG (2500 U/g), an endoxylanase product (EC 77 
3.1.2.8, family 11 of glycosyl hydrolases) from Thermomyces lanuginosus 78 
(donor)/Aspergillus oryzae (host) was kindly supplied by Novozyme (Bagsvaerd, 79 
Denmark). 1,4-α-D-Glucan-glucanohydrolase (α-Amylase heat stable, ≥500 U/ml) 80 
from Bacillus licheniformis and Proteinase (≥500 U/ml) from Aspergillus melleus 81 
were purchased from Sigma-Aldrich (Gillingham, UK). D-(+)-xylose for AXs 82 
determination was purchased from Acros Organics (Loughborough, UK). D-83 
glucose, D-xylose, D-arabinose, and D-galactose for determination of 84 
monosaccharide composition were purchased from Sigma–Aldrich (Gillingham, 85 
UK).   86 
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U937 cell line was purchased from the Public Health England Culture 87 
Collections. LPS (Lipopolysaccharides of E. coli serotype O111:B4,) used as a 88 
positive control in the in vitro experiments was purchased from Sigma-Aldrich, 89 
(Gillingham, UK). The medium of RPMI-1640 with L-Glutamine was purchased 90 
from Lonza (Verviers, Belgium). Foetal bovine serum and penicillin-streptomycin 91 
(10,000 units penicillin and 10mg streptomycin/ml) were purchased from Sigma-92 
Aldrich (St. Louis, MO, USA). Human iNOS enzyme (116μg/ml, Code: TP311819) 93 
was purchased from Cambridge Bioscience, UK. Primary antibody, monoclonal 94 
iNOS Antibody (4E5) was purchased from Novus Biologicals (Cambridge, UK). 95 
Secondary antibody, the Rabbit anti-mouse Immunoglobulins/HRP (code: P0260) 96 
was purchased from Dako (Glostrup, Denmark). 97 
Other chemicals including analytical grade acids, alkaline and organic solvents 98 
were purchased from Sigma Aldrich (Gillingham, UK). .  99 
2.2 Methods 100 
2.2.1 Extraction of AXs  101 
The AX extraction process was developed from the method of Li et al. (2013). 102 
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The Pentosan fraction of wheat flour was ground to a 0.5mm particle size using an 103 
Ultra Centrifugal Mill ZM 200 (RETSCH Ltd. United Kingdom). 30g of milled 104 
pentosan sample was mixed with 200g of distilled water using a hand blender 105 
(800W, WSB800U) for 45s. For the water extraction process, the pentosan-water 106 
mixture was incubated in a shaking water bath at 40°C for 2h followed by 107 
centrifugation (6000g, 20min), and the supernatant (containing extracted AX) was 108 
recovered for ethanol precipitation. In the enzymatic extraction process, the 109 
effects of three individual extraction conditions: concentration of endoxylanase 110 
(50, 100, 200, 300, 400ppm w/w), extraction time (2h, 3h, 4h) and temperature 111 
(20°C, 30°C and 40°C) on AX extraction yield and structures were studied.   112 
The AXs extraction  process was developed from the method of Li et al. 113 
(2015). The 150ml extraction supernatant was added to 300µl Termamyl α-114 
Amylase at 90°C to allow starch hydrolysis to occur. After 1h, the solution was 115 
cooled rapidly and adjusted to pH 7. Then, 100µl proteinase (1mg/ml, ≥3units/mg) 116 
was added to the solution and the mixture incubated at 60°C for 1h to remove 117 
protein from the supernatant and thenhe solution was placed in a boiling water 118 
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bath for 10min to deactivate the enzymes and cooled to the room temperature. 119 
After centrifugation at 6000g for 20min, the supernatant was collected and 120 
ethanol was added into the supernatant to a ratio of 70% of ethanol/supernatant 121 
(v/v).. The mixture was kept in the fridge overnight at 4°C. Then the mixture was 122 
centrifuged at 600g for 20min. After centrifugation, the residue was collected and 123 
washed with 20ml ethanol twice.. Then, the residue was placed in 20ml acetone 124 
and washed for 1min. After that, the residue was dried in an oven at 45°C overnight. 125 
The dried residue (dried AXs sample) was milled using an analytical mill (IKA A11 126 
Basic, Guangzhou, China, 50/60Hz, 160W). 127 
2.2.2 Determination of AXs extraction yields 128 
A standard curve for the determination of xylose was constructed using the 129 
method described by Douglas (1980). This curve was used for the determination 130 
of xylose content of raw material and extracted AX supernatants. The xylose 131 
content was then used to calculate the AX content of samples based on their A/X 132 
ratio as determined by mono-sugar composition analysis. The specific AX content 133 
is defined as the sum of the monosaccharide content, arabinose and xylose, times 134 
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0.88 to correct for hydration water (Swennen, Courtin, Lindemans, et al., 2006). 135 
Thus, the equation was: AX%=Xylose%×(1+A/X)×0.88. AX extraction 136 
yield=AX%×weight of supernatant (g)÷weight of raw material(g)×100.   137 
2.2.3 Determination of monosaccharide compositions of isolated AXs 138 
The monosaccharide compositions of AX samples were analysed using a 139 
method developed from that of Li et al. (2015). 1 ml of H2SO4 (1M) was added to 140 
20mg of dried AX sample, which  was hydrolysed at 100°C for 2h in a glycerin 141 
bath. The hydrolysed samples were transferred to a volumetric flask and diluted 142 
20 fold (1mg/ml) using HPLC grade water. The pH of diluted solution was adjusted 143 
to 6.5-7.2 with 1M NaOH. The solution was then filtered through a 0.45μm nylon 144 
membrane and transferred to a 1ml glass shell vial for HPLC analysis. In the HPLC 145 
analysis, the mobile phase was HPLC grade water at isocratic elution which 146 
wasachieved using a Shimadzu LC-10ADvp Pump. Samples were analysed on 147 
SUPELCOGEL Pb (5cm×4.6mm) and Phenomenex ThermaSphere TS-130 columns 148 
combined with a JASCO RI-2031 Refractive index (RI) Detector. All analyses were 149 
conducted in triplicate. 150 
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2.2.4 Molecular structure characterisation of extracted AXs 151 
Size exclusion high-pressure liquid chromatography (SE-HPLC) with a 152 
refractive index (RI) detector was used to determine the molecular weights and 153 
size distribution of extracted AXs samples using methods as described by Li et al. 154 
(2013). The average degree of polymerisation (avDP) was calculated by dividing 155 
the apparent peak molecular mass by the molecular mass of anhydropentose 156 
sugars (Courtin et al., 2008).  157 
The determination of the molecular weight of AX samples was carried out 158 
using SE-HPLC. Mobile phase (Buffer) consisted of 17g NaNO3 and 0.65g NaN3, 159 
dissolved in 2L HPLC grade water. Eight pullulan standards (Shodex, Shanghai, 160 
China) with molecular weights in the range of 5,000-800,000Da were used to 161 
construct a standard curve. The AXs samples were dissolved in buffer to make 162 
2mg/ml solutions and left overnight under gentle stirring. Then, they were filtered 163 
through a 0.45μm nylon membrane and transferred to SE-HPLC analysis. 164 
Mw distribution of the AXs were analysed by columns of BioSep-SEC-S 4000 165 
and BioSep-SEC-S 3000 (Phenomenex, Macclesfield, UK) combined with JASCO RI-166 
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2031 RI Detector (Jasco Corporation, Tokyo, Japan). The two columns were 167 
connected in series (BioSep-SEC-S 4000 first) were used to improve the peak 168 
shape of AXs samples. Running time was 60min for each sample and the flow rate 169 
was 0.6 ml/min. All analyses were conducted in duplicate.  170 
2.2.5 in vitro testing 171 
2.2.5.1 Cell culture 172 
The complete cell culture medium was prepared using RPMI-1640 with L-173 
glutamine (Lonza, Belgium) to which was added 10% foetal bovine serum (FBS) 174 
and 2% penicillin-streptomycin (P/S). The Human U937 macrophage cell line was 175 
grown in the complete culture medium in sterile tissue culture flasks in an 176 
incubator at 37°C with 5% CO2 in air atmosphere and subcultured every 2 days. 177 
2.2.5.2 Polysaccharides medium preparation 178 
 The extracted AX samples and LPS were dissolved in the RPMI-1640 medium 179 
with 5% FBS overnight at room temperature to allow the sample fully hydrated. 180 
Then, they were sterilised using 0.45μm sterile filters and were diluted into a 181 
series of concentrations (1, 5, 10, 50, 500 and 1000μg/ml) for cell culture testing. 182 
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The samples were stored at 4°C in sterile Falcon tubes (Fisher Scientific, UK).  183 
2.2.5.3 Cell viability and growth analysis 184 
The growth and viability of U937 cells with and without treatment of AX 185 
samples and LPS were assessed by cell count and trypan blue uptake. The U937 186 
cells (viability ≥90%) were centrifuged at 1000g for 10min and suspended in 187 
RPMI-1640 medium with 10% FBS such that the density of live cells was set at 188 
1×106/ml. 100μl cell suspension was pipetted into each well of a 96-well 189 
microplate. The AXs and LPS mediums prepared with three concentrations (50, 190 
500 and 1000μg/ml) were  pre-warmed to 37°C and then 100μl of medium, AXs 191 
medium and LPS medium  was added to six wells of containing cells and mixed 192 
thoroughly. After 24h incubation, 40μl of cell fluid was pipetted from each well into 193 
a tube, and 40μl of trypan blue (Sigma-Aldrich, UK) was added. The number of 194 
cells stained (nonviable cells) and unstained (viable cells) with trypan blue were 195 
counted using a TC10 automated cell counter (Bio-Rad, UK). The viability of cells 196 
was calculated as a percentage by dividing the number of viable cells against to 197 
total number cells (total number of viable and nonviable cells). 198 
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2.2.5.4 NO assay  199 
Griess’ reagent was freshly prepared for the NO assay according to the 200 
methods of Dawson and Dawson (1995) and Griess (1879). Griess’ reagent is 201 
made up by two components. Component A is 37.5mmol/L sulphanilamide with 202 
deionized water in 6.5mol/L HCl by 1:1 (v/v). Component B is N-1-203 
napthylethylenediamine dihydrochloride (NEED) in deionized water at 204 
12.5mmol/L.  205 
50μl of culture medium of U937 cells was pipetted into each well of a 96-well 206 
microplate and 50μl of each AX and LPS sample was added into appropriate wells  207 
and it was mixed thoroughly. The 50μl RPMI-1640 with 5% FBS medium was 208 
added to wells containing 50μl live cells as an untreated control. The microplates 209 
were incubated (37°C, 5% CO2) for 24 hours. Then, 50μl of Component A of Griess’ 210 
reagent was added to each well for 10 minutes at room temperature. 50μl of 211 
Component B of Griess’ reagent was then added to each well. After mixing,it was 212 
incubated at 4°C for 20 minutes. The absorbance of each well was measured at 213 
540nm using a microplate reader (Synergy HTX Multi-Mode Reader, Biotek, UK).  214 
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A nitrite standard reference curve was used to determine the concentration of 215 
nitrite in each experimental wells, which  were constructed using sodium nitrite 216 
(Sigma Aldrich, UK) diluted in RPMI-1640 medium at a range of concentrations (0, 217 
0.1, 1.0, 10, 25, 50, 80 and 100μM). 218 
2.2.5.5 iNOS expression analysis-Dot blot assay 219 
The dot blot method was used to determine the concentration of iNOS 220 
expressed by the cell lysates (Bloch  et al., 1999). U937 cells were treated 221 
respectively with the AXs and LPS samples (50μg/ml) for 24h. Then, 5µl of treated 222 
cell samples were individually added to 500µl lysis buffer samples (1:100 dilution). 223 
Human iNOS enzyme was diluted in iNOS protein standard buffer to give 1:2, 1:4, 224 
1:6, 1:8 and 1:10 standards. The cell lysis samples and standards were set out as 225 
5μl drops on the nitrocellulose membrane (NC 45 nitrocellulose membrane, Serva 226 
Electrophoresis GmbH, Heidelberg, Germany) with 5μl of BSA (1mg/ml BSA in 227 
deionized water) used as a negative control (no iNOS protein) in the dot blot. The 228 
membrane was transferred to a solution of the primary antibody. The blot was 229 
shacked at 60rpm at 4°C overnight (≤20h).shaking.   230 
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Following incubation the primary antibody solution was decanted and the 231 
membrane was washed using TBS buffer. Secondary antibody solution was added 232 
to the blot and the membrane was shaken at 60rpm at room temperature for 1h. 233 
The secondary antibody solution was removed and the membrane was washed 234 
using TBS buffer. Then, the chemiluminescent detection agent was added 235 
(Biological Industries (BI), Lichfield, UK). Then, the membrane was placed in a 236 
G:Box (Chemi HR16, Syngene, Cambridge, UK) for the images of membrane to be 237 
captured and processed. The Image J software (National Institute of Health, USA) 238 
was used to quantitatively determine the levels of iNOS. The dot blot assay of iNOS 239 
was repeated three times in separate experiments.  240 
2.2.6 Statistics  241 
The assays, unless otherwise stated, were performed in triplicate and the 242 
means were compared using one-way ANOVA. A value of p≤0.05 was chosen as the 243 
criterion of statistical significance. The data were expressed as means ± standard 244 
error. 245 
 16 
3. Results and Discussions 246 
3.1 AXs extraction from pentosan fraction of wheat flour  247 
In the present study, the AX content of pentosan fraction, which was separated 248 
from wheat flour through high pressure disintegrated process was determined as 249 
15.79±0.46% (dry basis). As table 1 shows, compared with water extraction, the 250 
AXs yield significantly increased from 7.54% to 12.83% (p<0.05) with increasing 251 
endoxylanase (P-BG) concentration, 0 to 400 ppm. Particularly, in the 252 
concentrations range of   50 ppm and 200 ppm, the  significant increases in 253 
extraction yield is positively corresponding to  the increase of endoxylanse 254 
concentration (p<0.05). Higher concentrations from 200ppm to 400ppm did not 255 
change the yield significantly further (P>0.05), indicating that the optimum 256 
combination for practical use in the extraction process could be based on a 257 
concentration range from 200ppm to 400ppm. In addition, the temperature of 258 
30C-40C showed a higher AX extraction yield using associated conditions of 259 
200ppm endoxylanase, 2h and pH 4.5 than other temperatures used in this study. 260 
Moreover, under the conditions:400 ppm endoxylanse,  at 40C for 2h, AXs 261 
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extraction from the pentosan fraction reached the highest recovery, which is 81.25% 262 
of the total AXs content.  263 
The major reason for the increased yield achieved using the 264 
endoxylansetreatment is that this enzyme is able to attack the xylan backbone, 265 
cleaving internal β-(1,4)-linkages and a portion of water un-extractable AXs 266 
(WUAXs) will be rendered soluble and extractable (Andersson et al., 2003; Li et al., 267 
2013; Swennen, Courtin, & Delcour, 2006). This means that   some WUAXs of 268 
cell wall in pentosan fraction was released into solution, which resulted in an 269 
increase in AXs extraction yield. According to the theory of enzyme kinetics, with 270 
a certain substrate concentration, the enzyme is merely a catalyst which given 271 
sufficient time could convert the substrate to the maximum extent (Berg et al., 272 
2002). However, considering the efficiency of the AX extraction process, the 273 
extraction time selected in this experiment was 2h as this would be appropriate 274 
for use in an industrial production system. The results indicated extraction 275 
temperature and endoxylanase concentration demonstrated significant effects on 276 
AX extraction yield.  277 
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3.2 Structural characterisation of AXs  278 
3.2.1 Monosaccharide compositions and branch degree analysis of AXs  279 
Table 2 shows that the enzyme extracted AXs samples (E-WEAXs) have a 280 
higher A/X ratio than water extracted AXs (WEAXs), and the increase of A/X ratio 281 
of E-WEAXs linearly associated with the concentration of endoxylanase from 282 
0ppm to 400ppm (R2=0.958). In fact, the A/X ratio represents the degree of 283 
branching of AXs, which is an indicator of the relative proportions of the 284 
substituted residues in xylan chains (Izydorczyk & Biliaderis, 2007). Therefore, 285 
the results indicate that AXs extracted from the pentosan fraction using the 286 
enzymatic treatments contain more substituted xylose residues. 287 
3.2.2 Molecular characterisation of AXs  288 
The overall Mw distribution of AXs ranged from 159Da to 794KDa (1×102.2-289 
105.9Da) and it was divided into four ranges (Table 2). The WEAX are mainly 290 
(78.52%) wiht the larger Mw range 10KDa to 794KDa (ranges 1 and 2) whereas 291 
E-WEAXs are mainly (81-89%) with the smaller Mw range 1KDa to 100KDa 292 
(ranges 2 and 3). As shown in Fig. 1, the Mw distribution curve of the E-WEAXs 293 
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contains two main peaks: the major one, Mw of 12.22KDa (log10Mw≈4.1), and the 294 
lesser, Mw of 3.72KDa (log10Mw≈3.6), for which the average degree of polymer 295 
(avDP) are 93 and 28 respectively. However, the WEAX sample comprises mainly 296 
one peak, 501.19KDa (log10Mw≈5.7), for which the avDP is 3797. In addition, Table 297 
2 shows that as the concentration of endoxylanase  increased from 50ppm to 298 
400ppm, the proportion of the E-WEAX in the small Mw ranges 3 and 4 (0.16KDa 299 
to 10KDa) increased from 39.19% to 54.36%, meanwhile the graph of Mw 300 
distribution (Fig. 1) shows that the Mw peak at around 3.72KDa (log10Mw≈3.6) as 301 
progressing enlarged with the concentration increase of endoxylanse According 302 
the previous studies,  endoxylanase attacked the β-1, 4 linked D-xylopyranosyl 303 
backbone and break down xylan chains, thus, reducing the molecular weight of 304 
AXs during enzymatic extraction (Courtin & Delcour, 2001; Izydorczyk & Biliaderis, 305 
2007). Zhang et al. (2014) indicated that the Mw of AXs varies depending on the 306 
extraction and treatment methods used. Endoxylanase treatment appears to be 307 
one of the most effective methods for modifying AXs with a relatively low Mw 308 
distribution.   309 
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3.3 Immunomodulatory activity of AXs with various molecular structures    310 
In order to further investigate the possible relationship between 311 
immunomodulatory activity and molecular structure, WEAX and E-WEAX 312 
(400ppm) with significantly different Mw distributions and monosaccharide 313 
compositions were selected for the in vitro studies.    314 
3.3.1 Effects of AXs on growth and viability of U937 cells 315 
As shown in Table 3, the total cell counts of U937 macrophages treated with 316 
AXs (50, 500, 1000μg/ml) are not significantly different compared to control 317 
(untreated cells) (p>0.05). Therefore, WEAX and E-WEAX did not present a 318 
stimulatory effect on the growth of U937 cells over the period of 24h. In addition, 319 
the viability of cells with AX treatments was typically 90%, which is similar to the 320 
control cells, suggesting that AX samples also have no significant effect on U937 321 
cell survival over the test period of 24h.  322 
However, the total counts of U937 cells were reduced significantly after 323 
treatment with 500 and 1000μg/ml LPS compared with untreated control cultures 324 
(p<0.05), showng  inhibitory effect on cell growth, but it  did not appear at 325 
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relatively low concentrations (50μg/ml) of LPS treatments. In addition, the 326 
viability of cells with LPS treatments did not show a significant difference 327 
compared with control cells (p>0.05), suggesting that LPS (50-1000μg/ml) has no 328 
effect on U937 cell survival over 24h. This suggests that high concentrations of LPS 329 
may have an inhibitory effect on U937 cell growth. Previous studies have indicated 330 
that LPS inhibits and blocks macrophage proliferation and it depended on the 331 
incubation time and dosage (Muller-Decker et al., 2005; Vadiveloo et al., 1996; 332 
Vairo et al., 1992). The inhibitory effect of LPS on cell proliferation was proposed 333 
to be tightly regulated through a complex network of cytokines. For example, 334 
Vadiveloo et al. (2001) found that bacterial LPS had an inhibitory effect on cell 335 
proliferation in mouse marrow-derived macrophages. They found LPS inhibited 336 
the expression of cyclin D1, which is an essential protein for proliferation in many 337 
cell types. 338 
Botanical polysaccharides extracted from plants have received considerable 339 
attention in bioscience due to their wide immunomodulatory activities and low 340 
toxicity (Schepetkin & Quinn, 2006). Compared with LPS, the present study 341 
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indicated that the AX extracts have no inhibitory effects on the viability and cell 342 
growth of the human U937 macrophage, even at 1000μg/ml.  343 
3.3.2 Effects of AXs on NO production by U937 cells 344 
Table 4 shows the NO production by U937 cells after treatment with WEAX, E-345 
WEAX and LPS over the concentration range from 1 to 500μg/ml. both AXs 346 
extracts significantly elevated NO production by U937 cells after 24h incubation 347 
period compared with the untreated control (p<0.05). Furthermore, the amount 348 
of NO production significantly increased with the treatment of 10μg/ml of E-349 
WEAX compared to with lower concentrations (p<0.05). The highest amount of 350 
NO released by the E-WEAX treatment was 67.77μM at 50μg/ml. However, there 351 
was a significant decrease in NO secretion following E-WEAX treatment at 352 
500μg/ml (p<0.05) compared to that at 50μg/ml. Unlike E-WEAX treatment, NO 353 
secretion increase by WEAX treatment appeared to be significant till the 354 
concentration reached 500μg/ml (p<0.1), suggesting the peak amount of NO 355 
released by the WEAX treatment may not have been reached. Hence, these results 356 
indicate that there is a possibly optimal dose of E-WEAX for NO production in the 357 
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range 10-50µg/ml whilst WEAX has a significantly different optimum dose above 358 
500µg/ml. In addition, in the concentration range from 10 to 50µg/ml, NO 359 
response of WEAX is much more modest than that produced by similar 360 
concentrations of E-WEAX (p<0.05). These comparisons show that there are 361 
obvious differences between E-WEAX and WEAX treatments in relation to NO 362 
stimulation, Again E-WEAX showed stronger immunomodulatory activity than 363 
WEAX in the present assay.  364 
Secondly, LPS, used as a positive control, significantly stimulated NO secretion 365 
at concentrations of 1 to 50μg/ml (Table 4) compared to the untreated control, 366 
which is similar to E-WEAX. However, at 500μg/ml of LPS, the amount of NO 367 
produced by the U937 cells significantly decreased (p<0.05) compared to lower 368 
concentrations of LPS, reflecting the substantial inhibitory effect on cell growth 369 
and viability at this concentration (Table 3). Compared with AXs, the NO produced 370 
following LPS treatment is consistently higher at the concentration range of 1 to 371 
50μg/ml.  372 
It is obvious that there is a relationship between Mw and structure of AXs and 373 
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their immunomodulatory activity. As shown, the main structural differences 374 
between these two AX samples was in the low Mw range of 1-10KDa. The E-WEAX 375 
contains a higher AX portion of AX with lower avDP in this small Mw range 376 
compared with WEAX. In addition, E-WEAX presented a higher A/X ratio (0.83) 377 
compared to WEAX (0.48). This means that the xylan chains of E-WEAX have more 378 
arabinose substitutes. Thus, the large difference in NO stimulatory activity 379 
between the two AX samples may be associated with the difference in the low 1-380 
10kDa Mw fraction and the higher A/X ratio.  381 
3.3.3 Effects of AX treatments on iNOS expression by U937 cells 382 
In order to obtain a better understanding of AX modulation of NO production, 383 
the effect of WEAX and E-WEAX on iNOS levels was determined using in vitro 384 
testing. As shown in Fig. 2A, the effect of AXs treatment on iNOS expression of 385 
U937 cells was detected by using dot blot. WEAX and E-WEAX significantly 386 
elevated the level of iNOS expression by U937 cells after a 24h incubation period 387 
compared with the control (p<0.05). From the result of the densitometry analysis 388 
shown in Fig. 2B, E-WEAX and WEAX resulted in a 2.6 and 2.1 fold increase in iNOS 389 
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concentration from U937 cell lysates respectively compared with the control. In 390 
addition, the amount of iNOS following treatment with E-WEAX was significantly 391 
higher than with WEAX (p<0.05). LPS was used as a positive control producing a 392 
significant increase in iNOS expression compared to control (p<0.05).  393 
It is obvious that the stimulatory effect of AXs on iNOS induction is highly 394 
correlated with their stimulatory activity on NO production. Therefore, the 395 
increased NO production by AXs treatment was possibly due to induced levels of 396 
iNOS by U937 cells. The LPS (positive control) also showed a high stimulatory 397 
activity on iNOS levels in U937 cell lysates in the testing. This is in agreement with 398 
the previous reports that the expression of iNOS in macrophage is induced by 399 
cytokines (such as IFN-γ and TNF-α) and microbial polysaccharides (such as LPS), 400 
which affect the conversion of L-arginine to citrulline by cationic amino acid 401 
transporters and the expression of both iNOS mRNA and protein (Bogdan, 2000). 402 
More recently a study found that polysaccharides from D. officinale were able to 403 
increase iNOS expression and NO production in RAW 264.7 cells. They indicated 404 
that the stimulatory ability of D. officinale polysaccharides on iNOS expression was 405 
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associated with the disruption of IκBα/NF-κB complexes, leading to the activation 406 
of NF-κB (H. Cai et al., 2015; H. L. Cai et al., 2012). Based on these previous reports, 407 
it is reasonable to propose that AXs may stimulate NO production in U937 cells 408 
through the iNOS pathway. Moreover, the dot blot experiment showed that E-409 
WEAX (50μg/ml) had a higher stimulatory effect on iNOS levels in U937 cell 410 
lysates compared to the effect of WEAX at the same concentration. The difference 411 
in stimulatory effect of E-WEAX and WEAX on iNOS induction overlaps with their 412 
significantly different stimulatory activity on NO production. Hence, AXs with 413 
different Mw distributions and branch degree may result in different stimulatory 414 
effects on the iNOS expression pathway in U937 cells and thus affecting theon NO 415 
production.  416 
4. Conclusions 417 
In this study, an enzymatic method has been developed to efficiently extract 418 
high yields of AXs with a high proportion of low MW material and a high degree of 419 
branching from wheat flour pentosan. The analysis of the relationship between the 420 
molecular structures and the immunomodulatory activity of AX samples in in vitro 421 
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testing suggests differences in the stimulatory effect on NO secretion are closely 422 
associated with the enzyme modified AXs which have a much higher proportion of 423 
lower Mw AXs and higher A/X ratio than the non-enzyme treated AXs. 424 
Furthermore, the effects of AXs on iNOS levels of human macrophage cells 425 
positively related to the increase in NO secretion, which suggest a pathway by 426 
which AXs modulate NO production in human macrophage cells. This is an exciting 427 
area for future research, the findings of which may elucidate the precise 428 
mechanism through which AXs modulate immune responses. 429 
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Table 1. The AXs extraction yield (dry basis) under different conditions of 566 
enzymatic treatment 567 
Treatment conditions Extraction yields of AXs  AX content of 
Raw material  
Treatment 
Temperature  
20C 11.12±0.39% a 
15.79±0.46% 
30C 12.97±0.34% b 
40C 12.73±0.53% b 
Treatment  
Time  
2 h 12.72±0.54% b 
3 h 12.21±0.34% b 
4 h 12.44±0.34% b 
Endoxylanase 
Concentration  
50ppm 10.31±0.26% a 
100ppm 10.71±0.55% a 
200ppm 12.70±0.55% b 
300ppm 12.75±0.40% b 
400ppm 12.83±0.35% b 
Control  Water extraction 7.54±0.47% c 
(20C-40C) means extracted AXs using the different enzyme treatment temperatures and other 568 
extraction conditions were set up as same (pH4.5, 2h, 200ppm endoxylanase); (2h-4h) means extracted 569 
AXs using the different enzyme treatment time and other extraction conditions were set up as same 570 
(pH4.5, 40C, 200ppm endoxylanase); (50-400ppm) means extracted AXs using enzymatic treatment at 571 
various concentrations at pH 4.5, 40C for 2h. The control indicates water extractable AX (WEAX) 572 
without enzymatic treatment. The extraction yields are presented as mean + SD and experiments were 573 
conducted in triplicate. The mean values with different letters (a, b and c) indicate significant differences 574 
(p<0.05) in AX extraction yield for each sample amongst all the treatments. The p-values were calculated 575 
by Student’s t-test using Excel.576 
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Table 2. The molecular structures of AX samples under different conditions of enzyme treatments 577 
Treatment conditions Monosaccharides compositions of AXs a Mw distributions of AXs c 








Control Water extraction 26.13±1.01 53.96 ±1.49 10.62±2.04 9.29 ±1.26 0.48 46.46% 32.06% 19.11% 2.37% 
Enzyme 
Concentration 
50ppm  28.15±1.34 49.65±1.22 11.92±0.95 10.28±1.32 0.57 15.27% 45.54% 35.42% 3.77% 
100ppm 29.93±0.69 47.92±2.02 11.42±0.83 10.74±1.23 0.62 9.26% 40.29% 46.72% 3.72% 
200ppm 26.77±1.23 37.13±0.76 20.3±0.86 15.81±0.32 0.72 7.17% 40.62% 46.82% 5.39% 
300ppm 27.11±0.76 35.37±2.92 21.32±1.03 16.2±1.43 0.77 6.47% 40.09% 48.88% 4.56% 
400ppm 28.74±1.77 34.51±0.34 21.85±2.22 14.9±2.32 0.83 5.75% 39.89% 49.51% 4.85% 
Treatment  
Time 
 2h  26.88±0.83 37.21±0.48 20.3±0.63 15.61±0.78 0.72 7.33% 40.18% 47.38% 5.11% 
 3h 27.52±0.34 38.22±1.32 19.84±0.63 14.42±0.79 0.72 7.48% 40.30% 47.04% 5.18% 
 4h 26.72±0.54 37.81±0.86 20.01±0.89 15.46±1.46 0.71 7.13% 40.45% 46.93% 5.49% 
Treatment 
Temperature 
 20C  27.11±1.82 39.04±1.64 18.47±1.33 15.38±0.49 0.70 7.15% 40.52% 46.87% 5.46% 
 30C 28.15±1.67 39.19±0.76 18.01±2.55 14.65±0.64 0.72 7.05% 40.69% 46.79% 5.47% 
 40C 26.67±1.05 37.22±0.35 20.34±0.50 15.77±0.44 0.72 7.23% 40.45% 46.75% 5.57% 
a: The proportion of each monosaccharide in AX sample is presented as mean + SD and all experiments were conducted in triplicate. b: A/X means the composition ratio of 578 
arabinose to xylose. c: The proportion of Mw in different range were analysed using the LC Data Analysis (SHIMADZU Corporation).  579 
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Table 3. Effects of AXs and LPS on the growth and viability of U937 cells 580 
Sample Concentration of AXs and LPS (μg/ml) Untreated Control  
 50 500 1000 
 Total count  Viability  Total count Viability  Total count Viability  Total count Viability  
LPS 1.18±0.029 92.63% 0.98±0.03* 92.33% 0.91±0.024* 88.15% 1.17±0.022 90.90% 
E-
WEAX 
1.21±0.021 90.60% 1.22±0.046 90.09% 1.23±0.032 90.70%   
WEAX 1.25±0.026 90.72% 1.23±0.016 90.48% 1.24±0.037 89.60%   
The total count (×106) indicated the count of total (viable and unviable) U937 cells after various 581 
treatments for 24h; the viability was calculated by viable cell count/total cell account; the total cell count 582 
and viability after AXs and LPS treatments were compared with the control (untreated by AXs or LPS) 583 
using the one way ANOVA; The symbol * indicated the p-value < 0.05; The total cell counts are presented 584 
as mean + SEM of six copies samples from experiment.585 
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Table 4. NO production by U937 cell under the treatment of WEAX, E-WEAX and LPS 586 
Samples Concentration of AXs and LPS (μg/ml) Untreated 


































The NO2- concentration (units: μM) described as mean + SEM is an indication of NO production in U937 587 
cells. The symbol * indicates NO secretion significantly increased (p<0.05) compared to the untreated 588 
control; The symbol # indicates NO secretion significantly changed (p<0.05) as the sample dosage 589 
progressively increased; The symbol @ indicates NO secretion with E-WEAX treatment was significantly 590 
different than with WEAX at that specific concentration (p-<0.05); The symbol $ indicates NO secretion 591 
with E-WEAX or WEAX treatment was significantly different than with LPS treatment at that specific 592 
concentration (p<0.05). The p-values were calculated by one-way ANOVA using SPSS.19 and experiments 593 
were conducted in triplicate.  594 
